Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2.
作者信息
Thieme Constantin J, Blazquez-Navarro Arturo, Safi Lema, Kaliszczyk Sviatlana, Paniskaki Krystallenia, Neumann Isabel E, Schmidt Kita, Stockhausen Mara, Hörstrup Jan, Cinkilic Ocan, Flitsch-Kiefner Linus, Meister Toni L, Marheinecke Corinna, Pfaender Stephanie, Steinmann Eike, Seibert Felix S, Stervbo Ulrik, Westhoff Timm H, Roch Toralf, Babel Nina
机构信息
Berlin Center for Advanced Therapies, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
出版信息
J Am Soc Nephrol. 2021 Nov;32(11):2725-2727. doi: 10.1681/ASN.2021050672.
Abstract
摘要
相似文献
1
Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2.在接受BNT162b2疫苗接种后，血液透析患者对关注变异株B1.1.7和B.1.351的体液免疫受损，但细胞免疫反应显著。
J Am Soc Nephrol. 2021 Nov;32(11):2725-2727. doi: 10.1681/ASN.2021050672.
2
Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.肾移植受者中 SARS-CoV-2 BNT162b2（tozinameran）疫苗加强接种后体液和细胞免疫受损。
J Clin Invest. 2021 Jul 15;131(14). doi: 10.1172/JCI150175.
3
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.1273-mRNA 新冠病毒疫苗接种后长期血液透析患者中产生强烈细胞和体液免疫应答。
Front Immunol. 2022 Mar 23;13:845882. doi: 10.3389/fimmu.2022.845882. eCollection 2022.
4
Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.血液透析患者的 SARS-CoV-2 疫苗免疫原性。
J Am Soc Nephrol. 2021 Nov;32(11):2735-2742. doi: 10.1681/ASN.2021040432. Epub 2021 Aug 4.
5
Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.血液透析患者和肾移植受者队列中 SARS-CoV-2 mRNA 疫苗接种后的体液反应。
J Am Soc Nephrol. 2021 Sep;32(9):2153-2158. doi: 10.1681/ASN.2021040490. Epub 2021 Jun 16.
6
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination.透析患者接种 SARS-CoV-2 mRNA 疫苗 4 个月后对关注变异体的免疫反应减弱。
Emerg Infect Dis. 2022 Apr;28(4):743-750. doi: 10.3201/eid2804.211907. Epub 2022 Feb 24.
7
Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.血液透析患者接种三剂 mRNA-BNT162b2 和腺病毒载体 Ad26COVS1 异源 SARS-CoV-2 疫苗后的体液和细胞免疫应答。
Front Immunol. 2022 Jun 23;13:907615. doi: 10.3389/fimmu.2022.907615. eCollection 2022.
8
Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.透析患者对基于mRNA与腺病毒载体的SARS-CoV-2疫苗的体液反应。
Clin J Am Soc Nephrol. 2021 Nov;16(11):1720-1722. doi: 10.2215/CJN.06450521. Epub 2021 Jul 26.
9
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.血液透析患者中 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗的真实世界有效性和免疫原性。
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
10
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.BNT162b2 mRNA 疫苗接种后细胞和体液功能反应在 COVID-19 初治和恢复期患者中具有纵向差异。
Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21.
引用本文的文献
1
Serological Correlate of Protection Established by Neutralizing Antibodies Differs Among Dialysis Patients with SARS-CoV-2 Variants of Concern.在感染新冠病毒变异株的透析患者中，由中和抗体建立的保护血清学关联存在差异。
Vaccines (Basel). 2025 May 13;13(5):518. doi: 10.3390/vaccines13050518.
2
The survival of B cells is compromised in kidney disease.在肾脏疾病中，B细胞的存活受到损害。
Nat Commun. 2024 Dec 30;15(1):10842. doi: 10.1038/s41467-024-55187-w.
3
Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents.恢复期儿童和青少年的 SARS-CoV-2 体液 VOC 交叉反应性减弱和持续的细胞免疫。
BMC Infect Dis. 2023 Nov 22;23(1):818. doi: 10.1186/s12879-023-08805-9.
4
COVID-19 Vaccination in Kidney Transplant Candidates and Recipients.肾移植候选者和接受者中的新冠病毒疫苗接种
Vaccines (Basel). 2022 Oct 27;10(11):1808. doi: 10.3390/vaccines10111808.
5
Humoral Immune Response to a Timely Booster mRNA Vaccination in Non-Responders to a Standard Vaccination Schedule against COVID-19 in Kidney Transplant Recipients.肾移植受者中对COVID-19标准疫苗接种方案无反应者及时接种加强mRNA疫苗后的体液免疫反应
J Clin Med. 2022 Oct 30;11(21):6439. doi: 10.3390/jcm11216439.
6
Vaccination in patients with kidney failure: lessons from COVID-19.肾衰竭患者的疫苗接种：COVID-19 带来的启示。
Nat Rev Nephrol. 2022 Nov;18(11):708-723. doi: 10.1038/s41581-022-00617-5. Epub 2022 Aug 23.
7
Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination.新冠病毒病全程接种疫苗后3个月内慢性肾脏病患者中SARS-CoV-2刺突蛋白反应性抗体和T细胞反应的动态变化
Clin Kidney J. 2022 Apr 9;15(8):1562-1573. doi: 10.1093/ckj/sfac093. eCollection 2022 Aug.
8
Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study.奥密克戎变异株感染的血液透析患者疫苗接种的结局和效果：一项队列研究。
Nephrol Dial Transplant. 2022 Sep 22;37(10):1944-1950. doi: 10.1093/ndt/gfac209.
9
Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.在血液透析患者中，第三次接种 BNT162b2 疫苗前后对 B.1.617.2（德尔塔）变异株的中和抗体活性。
Front Immunol. 2022 Mar 4;13:840136. doi: 10.3389/fimmu.2022.840136. eCollection 2022.
10
Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的信使核糖核酸（mRNA）疫苗在慢性肾脏病、血液透析及肾移植后的抗体反应
J Clin Med. 2021 Dec 28;11(1):148. doi: 10.3390/jcm11010148.
Zotero 插件